AI could predict Alzheimer’s disease risk
A new AI program can say with a high degree of accuracy whether someone will develop Alzheimer’s-linked dementia within six years.
Your mom may be a better health influencer than ‘The Rock’
Adults who said they looked to a person they knew as a health role model rather than a celebrity had greater motivation to reach their goals.
Store-bought tulips could be deadly
The soil and flower bulbs you buy for gardening may contain deadly fungi. “People don’t think of tulips as deadly, but they could be.”
Texas Startup Must Litigate Apple in California because of Convenience to the Tech Giant
by Dennis Crouch
The Federal Circuit recently denied a petition for mandamus seeking to overturn a district court order transferring a patent case from the Western District of Texas to the Northern District of California. In re Haptic, Inc., No. 2024-121 (Fed. Cir. June 25, 2024). This case was filed in Austin and assigned to Judge Robert Pittman with Haptic alleging that Apple’s “Back Tap” feature on iPhones infringes U.S. Patent No. 9,996,738 relating to gesture detection systems. Haptic is headquartered in Austin at the home of its longtime CEO and listed inventor Jake Boshernitzan. The company was part of Techstars Austin Accelerator as it developed its product known as Knocki that allows users to tap on ordinary surfaces to control various actions on phones and other devices. Knock on wood. The patent and Knocki product are designed to expand touch interfaces beyond traditional touchscreens, potentially opening up new modes of interaction with smart devices and appliances. The ‘738 patent particularly issue covers systems and methods for detecting tapping or knocking gestures on surfaces to control electronic devices.
Apple also has a major presence in Austin, with about 10,000 Austin employees and a billion-dollar second headquarters campus in the city.
Amarin v. Hikma: Federal Circuit reverses Inducement Dismissal in Skinny-Label Case
by Dennis Crouch
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 2023-1169 (Fed. Cir. June 25, 2024).
This is another “skinny label” generic pharmaceutical patent case. The basic setup involves a drug that has several different approved uses; with the branded manufacturer holding patents covering only some of the uses. The generic company is then permitted to sell the drug, but is labelled only for non-patented uses. These labels are known as carve-out or “skinny” labels under 21 U.S.C. § 355(j)(2)(A)(viii).
It is inevitable that people will purchase and use the generic drugs for the patented uses, and that the generic distributer will be accused accused of inducing those infringing acts. Although the generic typically makes a profit on these sales, it those profits pale in comparison to the profits lost by the branded company.
Amarin v. Hickma highlights some of the challenges that generics are facing when marketing drugs with these carved-out labels. One difficulty is that the FDA severely limits what the generic can say about the drug and its uses, and the carve-out is generally based upon statements made by the patentee.
Amarin v. Hikma: Federal Circuit reverses Inducement Dismissal in Skinny-Label Case
by Dennis Crouch
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 2023-1169 (Fed. Cir. June 25, 2024).
This is another “skinny label” generic pharmaceutical patent case. The basic setup involves a drug that has several different approved uses; with the branded manufacturer holding patents covering only some of the uses. The generic company is then permitted to sell the drug, but is labelled only for non-patented uses. These labels are known as carve-out or “skinny” labels under 21 U.S.C. § 355(j)(2)(A)(viii).
It is inevitable that people will purchase and use the generic drugs for the patented uses, and that the generic distributer will be accused accused of inducing those infringing acts. Although the generic typically makes a profit on these sales, it those profits pale in comparison to the profits lost by the branded company.
Amarin v. Hickma highlights some of the challenges that generics are facing when marketing drugs with these carved-out labels. One difficulty is that the FDA severely limits what the generic can say about the drug and its uses, and the carve-out is generally based upon statements made by the patentee.
ChatGPT shows hiring bias against people with disabilities
According to new research, ChatGPT shows bias against resumes with credentials that imply a disability—but it can improve.
Real-time health monitor could get power from blood
Researchers have proposed the first-ever device powered by blood, which could help diagnose diseases in remote areas.
How to get health benefits from ‘forest bathing’
“Forest bathing has been shown to benefit the nervous system, heart rate, and blood pressure.” Here are tips to get started.
Will changes to this year’s presidential debates matter?
Do presidential debates still matter? How will tweaks to the debates’ format change their impact? An expert digs in.